期刊
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
卷 46, 期 6, 页码 869-877出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/03639045.2020.1764027
关键词
3D printing; selective laser sintering; pharmaceuticals; in-process monitoring; quality defects; personalized medication
Food and Drug Administration (FDA) has approved a drug product (Spritam (R)) and many medical devices manufactured by three-dimensional printing (3DP) processes for human use. There is immense potential to print personalized medicines using 3DP. Many 3DP methods have been reported in the literature for pharmaceutical applications. However, selective laser sintering (SLS) printing has remained least explored for pharmaceutical applications. There are many advantages and challenges in adopting a SLS method for fabrication of personalized medicines. Solvent-free nature, availability of FDA approved thermoplastic polymer/excipients (currently used in hot melt-extrusion process), minimal/no post-processing step, etc. are some of the advantages of the SLS printing process. Major challenges of the technology are requirement of at least one thermoplastic component in the formulation and thermal stability of drug and excipients. This review provides an overview of the SLS printing method, excipient requirements, process monitoring, quality defects, regulatory aspects, and potential pharmaceutical applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据